| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 149, 407-428, Copyright © 1996 by American Society for Investigative Pathology
REGULAR ARTICLES |
E Santoni-Rugiu, P Nagy, MR Jensen, VM Factor and SS Thorgeirsson
Laboratory of Experimental Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, USA.
We have previously shown that co-expression of c-myc and transforming growth factor (TGF)-alpha as transgenes in mouse liver results in major enhancement of neoplastic development in this organ as compared with expression of either of these transgenes alone. In this report we describe in detail the progression from liver cell dysplasia to hepatocellular carcinomas (HCCs) occurring in the liver of c-myc/TGF- alpha and c-myc transgenic mice. Despite morphological similarities in the sequence of events between the two transgenic lines, the dramatic acceleration, extent, and severity of hepatic lesions in c-myc/TGF- alpha mice clearly demonstrated the synergistic effects of this transgenic combination. Although c-myc/TGF-alpha and c-myc females displayed longer latency and lower tumor incidence, the pathological changes were the same as those seen in the male mice, including the formation of HCCs, which are absent in TGF-alpha single-transgenic females. Tumors in single- and double-transgenic mice showed induction of the endogenous c-myc and TGF-alpha and, most frequently, unchanged or decreased epidermal growth factor receptor, further indicating the collaborative role of c-myc and TGF-alpha in providing a selective growth advantage to tumor cells independently of the epidermal growth factor receptor levels. To identify possible tumor precursors, we focused particularly on the dysplastic changes preceding and accompanying the appearance of preneoplastic and neoplastic lesions in the double-transgenic mice. Early on, these changes were characterized by the appearance of large dysplastic hepatocytes, mostly pericentrally, expressing high levels of TGF-alpha and uPA, as well as TGF-beta 1, particularly in apoptotic cells. After a short period of replication and expansion into the liver parenchyma, as well as penetration into the central veins, these cells underwent apoptotic cell death while preneoplastic and neoplastic lesions were forming. The peritumorous tissues also contained small dysplastic hepatocytes and oval-like cells, similar to those found in the tumors. Transplantation of the transgenic liver tissues harboring only dysplasia with or without vascular lesions onto nude mice was able to yield HCCs composed of small diploid cells, suggesting that initiated cells are generated during the early dysplastic phase and can progress to HCC. It is therefore likely that large dysplastic hepatocytes undergo apoptosis, which may be closely associated with the up-regulation of TGF-beta 1 and uPA, whereas other cells evolve into the precursor population for HCC. Due to the simultaneous presence of c-myc, TGF-alpha, and dysplasia in premalignant human liver diseases, our transgenic mouse system appears to be an appropriate model for studying human hepatocarcinogenesis.
This article has been cited by other articles:
 |
|
 |
|
  M. H. Walkup and D. A. Gerber Hepatic Stem Cells: In Search of Stem Cells, August 1, 2006; 24(8): 1833 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Calvisi and S. S. Thorgeirsson Molecular Mechanisms of Hepatocarcinogenesis in Transgenic Mouse Models of Liver Cancer Toxicol Pathol, January 1, 2005; 33(1): 181 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Calvisi, S. Ladu, V. M. Factor, and S. S. Thorgeirsson Activation of {beta}-catenin provides proliferative and invasive advantages in c-myc/TGF-{alpha} hepatocarcinogenesis promoted by phenobarbital Carcinogenesis, June 1, 2004; 25(6): 901 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Harada, H. Oshima, M. Katoh, Y. Tamai, M. Oshima, and M. M. Taketo Hepatocarcinogenesis in Mice with {beta}-Catenin and Ha-Ras Gene Mutations Cancer Res., January 1, 2004; 64(1): 48 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Qin Su and P. Bannasch Relevance of Hepatic Preneoplasia for Human Hepatocarcinogenesis Toxicol Pathol, January 1, 2003; 31(1): 126 - 133. [Abstract] [PDF]
|
|
|
|
|
|
M. Nakau, H. Miyoshi, M. F. Seldin, M. Imamura, M. Oshima, and M. M. Taketo Hepatocellular Carcinoma Caused by Loss of Heterozygosity in Lkb1 Gene Knockout Mice Cancer Res., August 15, 2002; 62(16): 4549 - 4553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nicholes, S. Guillet, E. Tomlinson, K. Hillan, B. Wright, G. D. Frantz, T. A. Pham, L. Dillard-Telm, S. P. Tsai, J.-P. Stephan, et al. A Mouse Model of Hepatocellular Carcinoma : Ectopic Expression of Fibroblast Growth Factor 19 in Skeletal Muscle of Transgenic Mice Am. J. Pathol., June 1, 2002; 160(6): 2295 - 2307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hufnagl, W. Parzefall, B. Marian, M. Kafer, K. Bukowska, R. Schulte-Hermann, and B. Grasl-Kraupp Role of transforming growth factor {alpha} and prostaglandins in preferential growth of preneoplastic rat hepatocytes Carcinogenesis, August 1, 2001; 22(8): 1247 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. Deane, M. A. Parker, R. Aramandla, L. Diehl, W.-J. Lee, M. K. Washington, L. B. Nanney, Y. Shyr, and R. D. Beauchamp Hepatocellular Carcinoma Results from Chronic Cyclin D1 Overexpression in Transgenic Mice Cancer Res., July 1, 2001; 61(14): 5389 - 5395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Calvisi, V. M. Factor, R. Loi, and S. S. Thorgeirsson Activation of {beta}-Catenin during Hepatocarcinogenesis in Transgenic Mouse Models: Relationship to Phenotype and Tumor Grade Cancer Res., March 1, 2001; 61(5): 2085 - 2091. [Abstract] [Full Text]
|
|
|
|
|
|
S.-L. Y. Feng, Y. Guo, V. M. Factor, S. S. Thorgeirsson, D. W. Bell, J. R. Testa, K. A. Peifley, and J. A. Winkles The Fn14 Immediate-Early Response Gene Is Induced During Liver Regeneration and Highly Expressed in Both Human and Murine Hepatocellular Carcinomas Am. J. Pathol., April 1, 2000; 156(4): 1253 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. d. L. Coste, A. Mignon, M. Fabre, E. Gilbert, A. Porteu, T. V. Dyke, A. Kahn, and C. Perret Paradoxical Inhibition of c-myc-induced Carcinogenesis by Bcl-2 in Transgenic Mice Cancer Res., October 1, 1999; 59(19): 5017 - 5022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Santoni-Rugiu, M. R. Jensen, V. M. Factor, and S. S. Thorgeirsson Acceleration of c-myc-Induced Hepatocarcinogenesis by Co-Expression of Transforming Growth Factor (TGF)-{alpha} in Transgenic Mice Is Associated with TGF-ß1 Signaling Disruption Am. J. Pathol., June 1, 1999; 154(6): 1693 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sanders and S. S. Thorgeirsson Phenobarbital promotes liver growth in c-myc/TGF-{alpha} transgenic mice by inducing hypertrophy and inhibiting apoptosis Carcinogenesis, January 1, 1999; 20(1): 41 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Wong, P. Lai, S.-W. Lee, S. Fan, E. Pang, C.-T. Liew, Z. Sheng, J. W.-Y. Lau, and P. J. Johnson Assessment of Genetic Changes in Hepatocellular Carcinoma by Comparative Genomic Hybridization Analysis : Relationship to Disease Stage, Tumor Size, and Cirrhosis Am. J. Pathol., January 1, 1999; 154(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Factor, A. Kiss, J. T. Woitach, P. J. Wirth, and S. S. Thorgeirsson Disruption of Redox Homeostasis in the Transforming Growth Factor-alpha /c-myc Transgenic Mouse Model of Accelerated Hepatocarcinogenesis J. Biol. Chem., June 19, 1998; 273(25): 15846 - 15853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Kumaraswamy, A. Malykh, K. V. Korotkov, S. Kozyavkin, Y. Hu, S. Y. Kwon, M. E. Moustafa, B. A. Carlson, M. J. Berry, B. J. Lee, et al. Structure-Expression Relationships of the 15-kDa Selenoprotein Gene. POSSIBLE ROLE OF THE PROTEIN IN CANCER ETIOLOGY J. Biol. Chem., November 3, 2000; 275(45): 35540 - 35547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Factor, D. Laskowska, M. R. Jensen, J. T. Woitach, N. C. Popescu, and S. S. Thorgeirsson Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model PNAS, February 29, 2000; 97(5): 2196 - 2201. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
